Ridaforolimus

Ridaforolimus

Ridaforolimus (also known as deforolimus) is an investigational mTOR inhibitor used in the treatment of cancer. It is designed to inhibit the mammalian target of rapamycin (mTOR), a serine/threonine-specific protein kinase that plays an important role in cell growth, proliferation, and survival by regulating transcription and translation. By inhibiting mTOR, ridaforolimus disrupts these processes, which can lead to the inhibition of tumor growth and proliferation.

Mechanism of Action

Ridaforolimus works by specifically inhibiting the mTOR pathway, which is a central regulator of cell metabolism, growth, proliferation, and survival. The mTOR pathway is often upregulated in many types of cancer, making it a critical target for cancer therapy. By binding to the mTOR complex, ridaforolimus halts the downstream signaling pathways, leading to a reduction in protein synthesis and cell cycle progression, ultimately inhibiting cancer cell growth and proliferation.

Clinical Trials

Ridaforolimus has been evaluated in various clinical trials for its efficacy and safety in treating different types of cancers, including sarcoma, breast cancer, prostate cancer, and lung cancer. While it has shown promise in some trials, the results have been mixed, and it has not yet received approval from regulatory bodies such as the U.S. Food and Drug Administration (FDA) for the treatment of any cancer.

Adverse Effects

The use of ridaforolimus, like other mTOR inhibitors, is associated with a range of adverse effects. Common side effects include mucositis, fatigue, thrombocytopenia (low platelet count), anemia (low red blood cell count), and neutropenia (low white blood cell count). Due to its immunosuppressive effects, there is also an increased risk of infections.

Current Status

As of the last update, ridaforolimus is still under investigation and has not been approved for the treatment of cancer by major regulatory agencies. Research continues to determine its potential role in cancer therapy, either as a monotherapy or in combination with other treatments.

See Also

• mTOR inhibitors
• Cancer therapy
• Clinical trial
• Protein kinase inhibitor

‎ ‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian